Health
Therapy
Cancer Prevention

Heron Therapeutics

$23.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-3.49%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell HRTX and other stocks, options, ETFs, and crypto commission-free!

About

Heron Therapeutics, Inc. Common Stock, also called Heron Therapeutics, is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. Read More The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.

Employees
198
Headquarters
San Diego, California
Founded
1983
Market Cap
1.86B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.05M
High Today
$24.87
Low Today
$23.74
Open Price
$24.52
Volume
586.36K
52 Week High
$42.90
52 Week Low
$21.25

Collections

Health
Therapy
Cancer Prevention
Pharmaceutical
Biotechnology
Medical
Technology

News

MarketBeatMar 7

Stock Price, News, & Analysis for Heron Therapeutics

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associat...

106
Yahoo FinanceFeb 22

Heron Therapeutics: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Friday reported a loss of $49.6 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 46 cents per share. The pharmaceutical company posted revenue of $28.8 million in the period, surpassing Street forecasts. Four analysts surveyed by Zacks expected $28.1...

371

Earnings

-$1.09
-$0.88
-$0.66
-$0.45
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.